Thermo Fisher Scientific Inc. $TMO Shares Acquired by Prestige Wealth Management Group LLC

Prestige Wealth Management Group LLC grew its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1,040.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,369 shares of the medical research company’s stock after acquiring an additional 1,249 shares during the quarter. Prestige Wealth Management Group LLC’s holdings in Thermo Fisher Scientific were worth $794,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Vanguard Group Inc. increased its position in shares of Thermo Fisher Scientific by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company’s stock worth $19,778,774,000 after purchasing an additional 288,296 shares during the last quarter. Capital World Investors increased its position in shares of Thermo Fisher Scientific by 7.4% during the 3rd quarter. Capital World Investors now owns 10,285,145 shares of the medical research company’s stock worth $4,988,132,000 after purchasing an additional 706,572 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Thermo Fisher Scientific by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 8,196,477 shares of the medical research company’s stock worth $4,728,129,000 after purchasing an additional 26,425 shares during the last quarter. Franklin Resources Inc. increased its position in shares of Thermo Fisher Scientific by 21.0% during the 3rd quarter. Franklin Resources Inc. now owns 5,925,671 shares of the medical research company’s stock worth $2,874,069,000 after purchasing an additional 1,028,125 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth about $3,072,744,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $482.40 on Friday. The business has a 50-day moving average of $480.30 and a 200 day moving average of $531.49. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $643.99. The stock has a market capitalization of $179.27 billion, a price-to-earnings ratio of 26.52, a price-to-earnings-growth ratio of 2.10 and a beta of 0.88. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. The company had revenue of $11.01 billion during the quarter, compared to analysts’ expectations of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.Thermo Fisher Scientific’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same period last year, the business posted $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be paid a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, June 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.34%.

Wall Street Analysts Forecast Growth

TMO has been the subject of a number of recent analyst reports. DZ Bank initiated coverage on Thermo Fisher Scientific in a research report on Friday, March 27th. They set a “buy” rating and a $610.00 price objective for the company. HSBC downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating and cut their price objective for the stock from $670.00 to $540.00 in a research report on Wednesday. Barclays lowered their target price on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating for the company in a report on Tuesday, April 14th. Jefferies Financial Group upgraded Thermo Fisher Scientific to a “strong-buy” rating in a report on Friday, April 24th. Finally, Stifel Nicolaus lowered their target price on Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating for the company in a report on Friday, April 24th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $613.67.

Insider Activity

In other news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the transaction, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.